The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|80|5|1139-1148

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.80, Iss.5, 2015-11, pp. : 1139-1148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IGFBP-3 Promoter Polymorphism -202A>C (rs2854774) Contributes to Prostate Cancer Risk: Evidence Based on 9,482 Subjects

By  

Urologia Internationalis, Vol. 93, Iss. 1, 2014-01 ,pp. : 100-107

Karger

Access to resources Recommend Favorite

Biomarker discovery in ovarian cancer

By Tung Celestine S   Wong Kwong-Kwok   Mok Samuel C  

Women's Health, Vol. 4, Iss. 1, 2008-01 ,pp. : 27-40

Future Medicine

Access to resources Recommend Favorite

rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 2, 2015-02 ,pp. : 184-191

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients

By  

Oncology Research and Treatment, Vol. 38, Iss. 6, 2015-05 ,pp. : 276-281

Karger

Access to resources Recommend Favorite

Plasma miR-221 as a Predictive Biomarker for Chemoresistance in Breast Cancer Patients who Previously Received Neoadjuvant Chemotherapy

By  

Oncology Research and Treatment, Vol. 34, Iss. 12, 2011-11 ,pp. : 675-680

Karger

Access to resources Recommend Favorite